Navigation Links
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Date:6/11/2009

08.

"During the past year we have maintained a strong cash position and continued to advance our product development programs despite the global financial turmoil," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "Over the next twelve months, we will continue to execute on our strategy to build a sustainable business through investment in the acquisition and development of innovative products that deliver significant value to patients, customers and our shareholders."

Total revenue for the fourth quarter of fiscal year 2009 was $4,594,000 compared to $3,301,000 for the same period in fiscal year 2008, an increase of 39%. Operating expenses for the fourth quarter of fiscal year 2009 were $7,809,000, compared to $7,165,000 for the same period in fiscal year 2008. Net loss for the fourth quarter 2009 was $2,693,000 or $0.09 per diluted share compared to a net loss of $3,198,000 or $0.10 per diluted share in the same period in fiscal year 2008.

Corporate Update

RG1068 for Imaging of the Pancreas

We are currently enrolling patients in a Phase 3 clinical trial of RG1068, synthetic human secretin, designed to assess the ability of RG1068 in combination with magnetic resonance imaging (MRI) to improve the detection of pancreatic duct abnormalities compared to MRI alone. Detailed visual assessment of the pancreatic ducts is important in the diagnosis and treatment of diseases such as acute and chronic pancreatitis. This study is being conducted at approximately 30 clinical sites within the U.S. and Canada and will enroll approximately 250 patients. We have made steady progress on enrollment and plan to complete this trial by the end of the year. The FDA has granted this program Fast Track Designation, a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and fill an unmet med
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
2. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
3. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
4. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
5. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
6. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
9. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
10. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
11. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
(Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
(Date:12/19/2014)... 2014 Decision Resources Group finds that the ... 12 percent compound annual growth rate through 2023. This ... and the increasing adoption of dental implants. Growing aesthetic ... also spur demand for dental biomaterials because they can ... treatments. Other key findings from Decision Resources ...
Breaking Biology Technology:Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... RADI Medical Systems today,announced improvements to ... Certus, which will begin shipments immediately., ... latest generation of the PressureWire(R) Certus features ... three key,advantages for physicians. The new large ...
... Calif., July 8 Telik, Inc.,(Nasdaq: TELK ... Bioorganic &,Medicinal Chemistry Letters describing a novel class ... a new treatment for diabetes.,These unique compounds are ... Telik to optimize the original lead structure identified ...
... July 8 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics,Inc. (OTC Bulletin ... firm specializing in the manufacture, research, development,marketing ... Dr.,Shuguang Fang, China-Biotics, Chief Technology Officer, has ... China,s 3rd Annual Food Safety Technology Forum,2008 ...
Cached Biology Technology:RADI Medical Systems Launches Next Generation PressureWire(R) Certus 2Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters 2China-Biotics, Inc. to Present at China's 3rd Annual Food Safety Technology Forum 2008 2China-Biotics, Inc. to Present at China's 3rd Annual Food Safety Technology Forum 2008 3
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... a year, researchers watched patiently as a few computer-simulated ... different shapes. In real time, this contortion takes only ... this suspended animation paid off, as the simulations uncovered ... , Howard Hughes Medical Institute (HHMI) scientists made ...
... dwelling at deep-sea hydrothermal vents opt for temperatures of ... choice of conditions, giving them the highest thermal preference ... for extreme temperatures may be the undersea worms' meal ... to access -- and feast on -- lush mats ...
... London shows that robot assisted knee surgery is ... team of surgeons tested whether Acrobot, a robotic ... partial knee replacement. Acrobot works by helping the ... with the existing bones. , The surgeons looked ...
Cached Biology News:Computer simulation hints at new HIV drug target 2Computer simulation hints at new HIV drug target 3Computer simulation hints at new HIV drug target 4Computer simulation hints at new HIV drug target 5Some like it hot: Worms at deep-sea vents favor a fiery 45-55°C 2Robot assisted surgery more accurate than conventional surgery 2
... unit with motorized heated lid and skirted inner ... for microarrays and chips. The four screw-down points ... force of the motorized lid is set with ... results. This interchangeable Moto Alpha unit functions on ...
... These skirted micro test tubes are ... of polypropylene, these tubes have uniform walls ... nonsterile, with separate O-ring screw caps. The ... and have an operating range from -55 ...
... carriers to suit the widest possible range ... science laboratory. Labware carriers can be placed ... is simple for the user, thanks to ... are correctly guided into position. This allows ...
... For affinity chromatography, Affi-Prep protein ... (IgG), selectively remove IgG prior to ... adsorb immune complexes for antigen purification. ... region of immunoglobulins, especially IgG from ...
Biology Products: